Seeking Alpha: Cyclacel on the Verge of Becoming a Competitor for Big Pharma

Cyclacel Pharmaceuticals (CYCC) has been raising the eyebrows of many investors recently. This multi-marketed company has several potential medications in its pipeline, including: acute myeloid leukemia, Phase III; myelodysplastic syndrome, Phase II; solid tumors, Phase I.

Read more »